TTI2

Across TCGA pan-cancer cohorts, TTI2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TTI2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TTI2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TTI2 is over-expressed in tumor.

HNSC, LUAD, and LSCC are the cancer types where TTI2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTI2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.482	<.001	11	view →
LUAD	Male	II,III,IV	+0.575	<.001	9	view →
LSCC	Female	II,III,IV	+0.549	<.001	8	view →
COAD	All	All	+0.307	.002	6	view →
CCRCC	All	All	+0.166	.005	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TTI2–HNSC

Open the HNSC breakdown →